Scarica l'app Stockscreener
29.07
3.84%
1.075
Dopo l'orario di chiusura:
29.00
-0.075
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Arrowhead Pharmaceuticals Inc. stock outlook for YEARPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
Arrowhead Pharmaceuticals Inc. stock trendline breakdownMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Should value investors consider Arrowhead Pharmaceuticals Inc.Share Buyback & Weekly Top Gainers Alerts - خودرو بانک
Is Arrowhead Pharmaceuticals Inc. stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - خودرو بانک
News impact scoring models applied to Arrowhead Pharmaceuticals Inc.July 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Can Arrowhead Pharmaceuticals Inc. grow without dilutionMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Can Arrowhead Pharmaceuticals Inc. be recession proof2025 Historical Comparison & Safe Entry Momentum Tips - خودرو بانک
Smart tools for monitoring Arrowhead Pharmaceuticals Inc.’s price action2025 Risk Factors & Consistent Growth Equity Picks - Newser
Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference - AInvest
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
What is Arrowhead Pharmaceuticals Inc. s 5 year growth outlookTrade Signal Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک
What’s next for Arrowhead Pharmaceuticals Inc. stock priceQuarterly Trade Review & Breakout Confirmation Trade Signals - Newser
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals shares rise 3.82% intraday after insider sold shares. - AInvest
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.2025 Fundamental Recap & Low Risk Growth Stock Ideas - Newser
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - MSN
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - Mitrade
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.July 2025 Retail & Verified Momentum Watchlists - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategiesPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time seriesQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Big Picture & Real-Time Buy Signal Notifications - خودرو بانک
Will breakout in Arrowhead Pharmaceuticals Inc. lead to full recoveryWatch List & Real-Time Market Sentiment Reports - Newser
Will Arrowhead Pharmaceuticals Inc. announce a stock splitWeekly Trend Report & AI Enhanced Trading Signals - خودرو بانک
Arrowhead Pharmaceuticals Inc (ARWR) Insider Sell: James Hamilto - GuruFocus
Analyzing recovery setups for Arrowhead Pharmaceuticals Inc. investorsJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - Newser
Analyzing net buyer seller activity in Arrowhead Pharmaceuticals Inc. - Newser
Arrowhead Pharmaceuticals' Chief Medical Officer Sells 15,000 Shares at $25/Share - AInvest
Arrowhead Pharmaceuticals at Cantor Global Healthcare: Strategic Moves and Market Positioning - Investing.com
Can a trend reversal in Arrowhead Pharmaceuticals Inc. lead to recoveryPortfolio Update Summary & Verified High Yield Trade Plans - Newser
Is Arrowhead Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Signals - Newser
Using data models to predict Arrowhead Pharmaceuticals Inc. stock movementShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits - Yahoo Finance
Arrowhead Pharmaceuticals at Citi’s Biopharma Conference: Strategic Insights - Investing.com
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01 - MarketScreener
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at 27.35 USD - Investing.com
Tick level data insight on Arrowhead Pharmaceuticals Inc. volatilityJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech
Arrowhead Pharma stock gets Buy rating reaffirmed by H.C. Wainwright - Investing.com
Arrowhead Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Profit Report & AI Forecast for Swing Trade Picks - Newser
Arrowhead Pharmaceuticals Inc. stock momentum explained2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Detecting price anomalies in Arrowhead Pharmaceuticals Inc. with AI2025 Fundamental Recap & High Accuracy Swing Trade Signals - Newser
Arrowhead Pharmaceuticals shares fall 1.40% premarket after announcing a global licensing and collaboration agreement with Novartis for ARO-SNCA. - AInvest
Using Ichimoku Cloud for Arrowhead Pharmaceuticals Inc. technicalsPortfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Arrowhead Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Stocks To Watch: Arrowhead Pharm Sees RS Rating Jump To 89 - Investor's Business Daily
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):